M. Schwab

Pharmacology · Pharmacology and Therapeutics · 2001–2018

A researcher in the Science corpus: 10 papers; trusts 4 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom M. Schwab trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. D. Nebert
  2. Magnus Ingelman-Sundberg
  3. Ulrich M. Zanger

Papers from M. Schwab's perspective

Ordered by how strongly the researchers M. Schwab trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response (Molecular Psychiatry)
  2. The Cytochrome P450 2B6 (CYP2B6) Is the Main Catalyst of Efavirenz Primary and Secondary Metabolism: Implication for HIV/AIDS Therapy and Utility of Efavirenz as a Substrate Marker of CYP2B6… (Journal of Pharmacology and Experimental Therapeutics)
  3. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. (The Lancet)
  4. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR‐1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus (Clinical pharmacology and therapy)
  5. Clinical importance of the cytochromes P450. (The Lancet)
  6. Sex Differences in Pharmacokinetics and Pharmacodynamics (Clinical Pharmacokinetics)
  7. Role of Aryl Hydrocarbon Receptor-mediated Induction of the CYP1 Enzymes in Environmental Toxicity and Cancer* (Journal of Biological Chemistry)
  8. Cytochrome p-450 polymorphisms and response to clopidogrel. (New England Journal of Medicine)
  9. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. (Blood)
  10. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. (New England Journal of Medicine)

Their papers